Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4646 and Rifabutin Drug-Drug Interaction Study
NCT07199452Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-4646 in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Started Oct 2025; status: completed.
02
Drugs
MK-4646
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07199452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199452.